Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis

AIMS/INTRODUCTION: Patients with type 2 diabetes mellitus have a higher bone fracture risk than patients without diabetes. Although denosumab (Dmab) is a potent bone resorption inhibitor, its efficacy in patients with type 2 diabetes mellitus has not been elucidated. In this study, we investigated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyoshi, Arina, Kameda, Hiraku, Nagai, So, Nakamura, Akinobu, Miya, Aika, Takase, Takahiro, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264394/
https://www.ncbi.nlm.nih.gov/pubmed/33141482
http://dx.doi.org/10.1111/jdi.13458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264394/
https://www.ncbi.nlm.nih.gov/pubmed/33141482
http://dx.doi.org/10.1111/jdi.13458

Ejemplares similares